Gefässchirurgie

, Volume 16, Issue 7, pp 462–468 | Cite as

Nephrogene systemische Fibrose (NSF): Wie hoch ist das Risiko und wie können wir es vermeiden?

Leitthema

Zusammenfassung

Das Krankheitsbild der nephrogenen systemischen Fibrose, das nach Durchführung einer Gadolinium unterstützen Magnetresonanztomographie/-angiographie bei Patienten mit schwerer Niereninsuffizienz auftreten kann, hat zu einer massiven Verunsicherung in der Anwendung dieser wertvollen Untersuchungstechnik geführt. Das Ziel der vorliegenden Arbeit ist es, neben der Diskussion des Krankheitskonzepts, der zugrundeliegenden Pathophysiologie, der Klinik und der therapeutischen Optionen, die Risikofaktoren zu beleuchten und Konzepte der Prävention aufzuzeigen.

Schlüsselwörter

Gadolinium Magnetresonanztomographie Kontrastmittel Niereninsuffizienz Nephrogene systemische Fibrose 

Nephrogenic systemic fibrosis: what is the risk and how to prevent it?

Abstract

Nephrogenic systemic fibrosis is a severe systemic disease which can occur in patients with severe chronic kidney disease or acute kidney injury after the administration of gadolinium-based contrast agents. This observation led to a great uncertainty in the use of gadolinium-enhanced magnetic resonance imaging techniques. The purpose of this review is to discuss the concept of the disease, the clinical aspects, prognosis and therapeutic options. In particular, the risk factors involved are emphasized and preventive measures presented.

Keywords

Gadolinium Magnetic resonance imaging Contrast agent Chronic kidney disease Nephrogenic systemic fibrosis 

Literatur

  1. 1.
    Anonymous (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S 1–S 266Google Scholar
  2. 2.
    Bongartz G, Weishaupt D, Mayr M (2008) Neue Kontrastmittelproblematik bei Niereninsuffizienz: Gadolinium-induzierte Nephrogene Systemische Fibrose (NSF). Schweiz Med Forum 8:116–123Google Scholar
  3. 3.
    Braverman IM, Cowper S (2010) Nephrogenic systemic fibrosis. F1000 Med Rep 2:84PubMedCrossRefGoogle Scholar
  4. 4.
    Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001PubMedCrossRefGoogle Scholar
  5. 5.
    Cowper SE, Su LD, Bhawan J et al (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383–393PubMedCrossRefGoogle Scholar
  6. 6.
    Cowper SE (2005) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46:763–765PubMedCrossRefGoogle Scholar
  7. 7.
    Cowper SE Nephrogenic Fibrosing Dermopathy [ICNSFR Website]. 2001–2009. Available at http://www.icnsfr.org. Zugegriffen: 25. Juni 2011Google Scholar
  8. 8.
    Cuffy MC, Singh M, Formica R et al (2011) Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 26:1099–1101PubMedCrossRefGoogle Scholar
  9. 9.
    European Medicines Agency (2011) http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015569.pdf. Accessed 25.06.11Google Scholar
  10. 10.
    Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108PubMedCrossRefGoogle Scholar
  11. 11.
    Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [erratum]. Nephrol Dial Transplant 21:1745CrossRefGoogle Scholar
  12. 12.
    High WA, Ayers RA, Cowper SEJ (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:710–712PubMedCrossRefGoogle Scholar
  13. 13.
    Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491–502PubMedCrossRefGoogle Scholar
  14. 14.
    Ledneva E, Karie S, Launay-Vacher V et al (2009) Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 250:618–628PubMedCrossRefGoogle Scholar
  15. 15.
    Leiner T, Kucharczyk W (2009) NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging 30:1357–1363PubMedCrossRefGoogle Scholar
  16. 16.
    Leung N, Shaikh A, Cosio FG et al (2010) The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. Am J Transplant 10:558–562PubMedCrossRefGoogle Scholar
  17. 17.
    Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362PubMedCrossRefGoogle Scholar
  18. 18.
    Martin DR, Semelka RC, Chapman A et al (2009) Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 30:1350–1356PubMedCrossRefGoogle Scholar
  19. 19.
    Mayr M, Burkhalter F, Bongartz G (2009) Nephrogenic systemic fibrosis: clinical spectrum of disease. J Magn Reson Imaging 30:1289–1297PubMedCrossRefGoogle Scholar
  20. 20.
    National Kidney Foundation. Calculators for Health Care Professionals. http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfmGoogle Scholar
  21. 21.
    Newton BB, Jimenez SA (2009) Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 30:1277–1283PubMedCrossRefGoogle Scholar
  22. 22.
    Panesar M, Banerjee S, Barone GW (2008) Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant 22:803–808PubMedCrossRefGoogle Scholar
  23. 23.
    Perazella MA (2007) Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2:200–202PubMedCrossRefGoogle Scholar
  24. 24.
    Prince MR, Zhang HL, Roditi GH et al (2009) Risk factors for NSF: a literature review. J Magn Reson Imaging 30:1298–1308PubMedCrossRefGoogle Scholar
  25. 25.
    Prince MR, Zhang H, Zou Z et al (2011) Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 196:W138–W143PubMedCrossRefGoogle Scholar
  26. 26.
    Roditi G, Maki JH, Oliveira GJ et al (2009) Renovascular imaging in the NSF Era. Magn Reson Imaging 30:1323–1334CrossRefGoogle Scholar
  27. 27.
    Sherry AD, Caravan P, Lenkinski RE (2009) Primer on gadolinium chemistry. J Magn Reson Imaging 30:1240–1248PubMedCrossRefGoogle Scholar
  28. 28.
    Sieber MA, Steger-Hartmann T, Lengsfeld P et al (2009) Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging 30:1268–1276PubMedCrossRefGoogle Scholar
  29. 29.
    Swaminathan S, Shah SV (2007) New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18:2636–2643PubMedCrossRefGoogle Scholar
  30. 30.
    U.S. Food and Drug Administration. Available at http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed 25.06.11Google Scholar
  31. 31.
    Wang Y, Alkasab TK, Narin O et al (2011) Incidence of Nephrogenic Systemic Fibrosis after Adoption of Restrictive Gadolinium-based Contrast Agent Guidelines. Radiology 260:105–111PubMedCrossRefGoogle Scholar
  32. 32.
    Weinreb JC, Abu-Alfa AKJ (2009) Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? Magn Reson Imaging 30:1236–1239CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Medizinische PoliklinikUniversitätsspital BaselBaselSchweiz
  2. 2.Institut für RadiologieUniversitätsspital BaselBaselSchweiz

Personalised recommendations